Gender Bias and Overtreatment in Primary Care
Epidemiological Study on Gender Bias and Overtreatment in Primary Care Setting
Study Overview
Status
Conditions
Detailed Description
First, using the Delphi technique, a consensus will be reached on those "Do Not Do" recommendations that should be included in the retrospective analysis study. The selection criteria for these recommendations will be if they are about pharmacological treatments, considered to persist in clinical practice in primary care, their relationship with factors associated with sex and gender, and if ignoring the "Do not do" recommendation could cause a serious adverse event.
Second, a retrospective cohort study will be carried out including patients who attended primary care consultation in Alicante from 1st January 2022 to 31st December 2022. Data source will be the electronic record management system of the autonomous community of Valencia (named ABUCASIS), and they will be provided by the Ambulatory Assistance Information System (SIA-GAIA). Investigators will analyze the frequency of ignoring the "Do not do" recommendations previously selected by consensus by sex and age range.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alicante
-
San Juan De Alicante, Alicante, Spain, 03550
- Hospital San Juan de Alicante
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Attending primary care consultation from 1 January 2022 to 31 December 2022.
- Adults
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of female patients who were recommended "do not do"
Time Frame: From 1st January 2022 to 31 December 2022
|
Number of female patients who were recommended "do not do"
|
From 1st January 2022 to 31 December 2022
|
|
Number of male patients who were recommended "do not do"
Time Frame: From 1st January 2022 to 31 December 2022
|
Number of male patients who were recommended "do not do"
|
From 1st January 2022 to 31 December 2022
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- OVERGEND Data
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Any Condition
-
University of PittsburghCompleted
-
Instituto de Investigación Sanitaria de la Fundación...Hospital Universitario La PazCompleted
-
University of Texas at AustinSuspended
-
University of California, San FranciscoTerminated
-
VasoNova, Inc.CompletedAny Condition Requiring a PICC PlacementUnited States
-
Universitätsklinikum Hamburg-EppendorfCompletedAny Condition Treated in Primary CareGermany
-
University Hospital, Basel, SwitzerlandMedgate AG, Switzerland; HMO Gesundheitsplan Basel, SwitzerlandCompleted
-
Louis Bolk InstituteNational Research Centre of Complementary and Alternative Medicine, Norway; Healing SpaceCompletedThe Focus of the Study is on Any Volunteer With Any Symptom or ConditionNetherlands
-
Aveiro UniversityCompletedOlder Adults Without Any Specific Clinical ConditionPortugal
-
Medtronic - MITGCompletedAny Gastric Condition Which Requires Capsule EndoscopyGermany, Spain